SCHEMBL5649679

SCHEMBL5649679

CNc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)c(C2=CC(=O)C=CC2=O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 12/20 0.53
EGFR P00533 12/20 0.53
LCK P06239 3/20 0.53
CLK1 P49759 1/20 0.51
ABCG2 Q9UNQ0 1/20 0.51
SRC P12931 2/20 0.51
RET P07949 3/20 0.49
FLT1 P17948 2/20 0.49
FGFR1 P11362 1/20 0.49
GAK O14976 1/20 0.49
RIPK2 O43353 1/20 0.49
STK10 O94804 1/20 0.49
FLT3 P36888 1/20 0.49
JAK3 P52333 1/20 0.49
AAK1 Q2M2I8 1/20 0.49
Q6ZSR9 Q6ZSR9 1/20 0.49
SLK Q9H2G2 1/20 0.49
IRAK4 Q9NWZ3 1/20 0.49
RPS6KA6 Q9UK32 1/20 0.49
ALK Q9UM73 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650880 0.88 KDR (0.63) KDREGFRSRCRETFLT1
SCHEMBL5647981 0.88 EGFR (0.62) KDREGFRLCKCLK1ABCG2
SCHEMBL5652725 0.86 KDR (0.52) KDREGFRSRCRETFLT1
SCHEMBL5652946 0.86 KDR (0.57) KDREGFRLCKSRCRET
SCHEMBL5650381 0.86 KDR (0.52) KDREGFRLCKSRCRET
SCHEMBL5649566 0.85 EGFR (0.57) KDREGFRLCKABCG2SRC
SCHEMBL5654477 0.83 KDR (0.61) KDREGFRLCKCLK1ABCG2
SCHEMBL5649287 0.83 EGFR (0.60) KDREGFRLCKSRCRET
SCHEMBL5066045 0.83 KDR (0.66) KDREGFRFLT1FGFR1
SCHEMBL5647109 0.82 KDR (0.51) KDREGFRLCKSRCRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299092-A1 Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors WYETH (US) 2007-12-27 US claimed
WO-2005115145-A2 QUINONE SUBSTITUTED QUINAZOLINE AND QUINOLINE KINASE INHIBITORS WYETH (US) 2005-12-08 WO claimed
US-20070299092-A1 Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors WYETH (US) 2007-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299092-A1 Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors KDR, FLT1, FLT4 KDR 1/4885EGFR 439/4885LCK 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.